Previous 10 | Next 10 |
Enrollment of the Phase 3 CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) for multiple myeloma patients with 1-3 prior lines of therapy was completed by Janssen Biotech, Inc. U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act...
Updated data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated adults with multiple myeloma will be featured in an oral presentation First look at data from Cohort B of the CARTITUDE-2 study of cilta-cel in earlier lines of treatment, as well as updated data fr...
Gainers: SAB Biotherapeutics SABS+36%. Brightcove (NASDAQ:BCOV) +14%. Harmonic HLIT+9%. GDS Holdings Limited (NASDAQ:GDS) +7%. ZoomInfo Technologies ZI +5%. Losers: Cipher Mining CIFR -12%. Automatic Data Processing (NASDAQ:ADP) -9%. Legend Biotech Corporation(LEGN -9...
Legend Biotech (NASDAQ:LEGN) has lost ~9.2% in the post-market after the company announced that the FDA has extended the Prescription Drug User Fee Act (“PDUFA”) target date for ciltacabtagene autoleucel (“cilta-cel”) to Feb. 28, 2022. Legend (LEGN) ...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for cil...
You can read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Legend Biotech Corporation (NASDAQ:LEGN) traded today at a new 52-week high of $56.50. This new high was reached on below average trading volume as 149,000 shares traded hands, while the average 30-day volume is approximately 388,000 shares. In the past 52 weeks, Legend Biotech Corporati...
Legend Biotech Corporation (NASDAQ:LEGN) traded at a new 52-week high today of $54.75. Approximately 149,000 shares have changed hands today, as compared to an average 30-day volume of 372,000 shares. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the...
Shares of Legend Biotech Corporation (NASDAQ:LEGN) traded at a new 52-week high today of $52.57. Approximately 149,000 shares have changed hands today, as compared to an average 30-day volume of 374,000 shares. Legend Biotech Corporation (NASDAQ:LEGN) has potential upside of 10.6% based ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...